Preclinical molecular imaging developer MILabs has taken an order for its U-SPECT/CT system from the BC Cancer Agency in Vancouver, British Columbia, to expand its molecular oncology imaging and research capabilities.
The U-SPECT/CT unit is designed to detect heterogeneous molecular processes in tumors, according to MILabs.